loader2
Partner With Us NRI

May 24, 2022 03:59 PM

Company details

12.76
13.25
12.36
17.44
6M Return -5.61%
1Y Return -11.73%
Mkt Cap.(Cr) -
Volume 169,835
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 169,835

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

No Data Found
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found

Information

  • About Company
  • Company Info
  • Listing Info
0
0%
14.54
0%
0%

No Data Found

AGM Date (Month) :
Face Value Equity Shares :
Market Lot Equity Shares :
BSE Code : 535384
NSE Code : PHARMABEES
Book Closure Date (Month) :
BSE Group :
ISIN : INF204KC1089

ICICIdirect Nippon India NIFTY Pharma ETF Growth Plan FAQ

You can buy Nippon India NIFTY Pharma ETF Growth Plan shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Nippon India NIFTY Pharma ETF Growth Plan Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 24, 2022 03:59 PM the closing price of Nippon India NIFTY Pharma ETF Growth Plan was ₹ 12.79.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 24, 2022 03:59 PM, the market cap of Nippon India NIFTY Pharma ETF Growth Plan stood at ₹ 0.00.
The latest PE ratio of Nippon India NIFTY Pharma ETF Growth Plan as of May 24, 2022 03:59 PM is 0
The latest PB ratio of Nippon India NIFTY Pharma ETF Growth Plan as of May 24, 2022 03:59 PM is 1.12
The 52-week high of Nippon India NIFTY Pharma ETF Growth Plan is ₹ 17.44 while the 52-week low is ₹ 12.36 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE